GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...
GSK has spent slightly more on lobbying this year compared with 2023. The company spent $3.87 million in the first three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback